Nymox Pharmaceutical is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia and the treatment of low-grade localized prostate cancer. Co. has developed and markets NicAlert and TobacAlert, which is a test strips for determining whether a person is using tobacco products (NicAlert) or has been exposed to second-hand smoke (TobacAlert). The technology can be used with saliva as well as urine samples to detect tobacco product use. Co. also has developed AlzheimAlert, a proprietary urine assay for the diagnosis of Alzheimer's disease. Co. has developed a kit version of the AlzheimAlert assay for sale in Europe. The NYMX stock yearly return is shown above.
The yearly return on the NYMX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NYMX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|